Clinical risk factors for the development of tardive dyskinesia.

@article{Solmi2018ClinicalRF,
  title={Clinical risk factors for the development of tardive dyskinesia.},
  author={Marco Solmi and G Giorgio Pigato and John M. Kane and Christoph U Correll},
  journal={Journal of the neurological sciences},
  year={2018},
  volume={389},
  pages={21-27}
}
BACKGROUND Tardive dyskinesia (TD) is a severe condition that can affect almost 1 out of 4 patients on current or previous antipsychotic treatment, including both first-generation antipsychotics (FGAs) and second-generation antipsychotics (SGAs). While two novel vesicular monoamine transporter inhibitors, deutetrabenazine and valbenazine, have shown acute efficacy for TD, the majority of patients do not remit, and TD appears to recur once treatment is withdrawn. Hence, prevention of TD remains… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 21 extracted citations

Similar Papers

Loading similar papers…